Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Onabotulinum Toxin A-Led Urinary Tract Infections-Should we Safeguard? A Randomized Controlled Trial.
Int Urogynecol J
January 2025
Department of Urogynecology and Reconstructive Pelvic Surgery, Atlantic Health System, 435 South Street, Suite 370, Morristown, NJ, 07960, USA.
Introduction And Hypothesis: The objective of our study was to evaluate the need for antibiotic prophylaxis for urinary tract infection (UTI) prevention before Onabotulinum toxin A injection for overactive bladder (OAB). We hypothesize that the lack of antibiotic prophylaxis might not be inferior to administering prophylaxis.
Methods: This was a multi-centered, nonblinded, randomized controlled trial conducted between August 2022 and September 2024.
Plain Language Summary of Publication: What is the effect of the medicine vibegron in the treatment of overactive bladder in patients with and without bladder leakage?
Ther Adv Urol
January 2025
Sumitomo Pharma America, Inc., Marlborough, MA, USA.
What is this summary about? People with overactive bladder need to use the bathroom many times a day to urinate (pee). This need may often be sudden and may cause some people with overactive bladder to have accidental bladder leakage. The EMPOWUR trial looked at how well a medicine called worked to help people with overactive bladder.
View Article and Find Full Text PDFUnderstanding and Managing Pediatric Urinary Tract Infections in Vesicoureteral Reflux: Insights Into Pathophysiology and Care.
Cureus
December 2024
General Practice, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, SAU.
Vesicoureteral reflux (VUR) is a pediatric condition identified by the backward flow of urine from the bladder to one or both ureters and kidneys, predisposing patients to recurrent urinary tract infections (UTIs) and kidney scarring. Continuous antibiotic prophylaxis has long been a mainstay of management aimed at preventing recurrent UTIs and resulting renal damage. This review critically discusses the evidence supporting the utilization of antibiotic prophylaxis in VUR, with a focus on its efficacy, safety, long-term outcomes, and future directions in management.
View Article and Find Full Text PDFDrug-induced urinary retention: a real-world pharmacovigilance study using FDA and Canada vigilance databases.
Front Pharmacol
January 2025
Department of Urology, The First Hospital of Jilin University, Changchun, China.
Background: Urinary retention (UR) is a clinical condition where patients cannot fully empty their bladder. Although numerous drugs are associated with UR, comprehensive and reliable studies identifying drugs that induce UR are scarce.
Methods: This study leveraged data from the FDA Adverse Event Reporting System (FAERS) and the Canadian Vigilance Adverse Reaction (CVAR) database to explore adverse events (AEs) related to UR from 2004 to Q1 2024.
Recent advances in innovative biomaterials for promoting bladder regeneration: processing and functionalization.
Front Bioeng Biotechnol
January 2025
The Second Hospital of Jilin University, Changchun, China.
The bladder is a dynamic organ located in the lower urinary tract, responsible for complex and important physiological activities in the human body, including collecting and storing urine. Severe diseases or bladder injuries often lead to tissue destruction and loss of normal function, requiring surgical intervention and reconstruction. The rapid development of innovative biomaterials has brought revolutionary opportunities for modern urology to overcome the limitations of tissue transplantation.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!